New Tools Not Inspi...
Health Care: Drugs
Oncolytics Biotech Inc. (ONCY: NASDAQ)
$2.34 -0.03 | -1.27%
06/17/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 19.42M | 32.24M | 39.29M | 30.99M |
| Receivables | 45.21K | 54.25K | 284.94K | 61.87K |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 21.78M | 34.90M | 43.46M | 33.14M |
| Property, Plant & Equipment, Gross | 1.13M | 978.00K | 740.64K | 629.44K |
| Accumulated Depreciation & Depletion | 719.43K | 593.96K | 513.76K | 430.49K |
| Property, Plant & Equipment, Net | 411.37K | 384.05K | 226.87K | 198.95K |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 0.00 | 0.00 | 735.56K | 653.23K |
| Total Non-Current Assets | 411.37K | 384.05K | 962.44K | 852.18K |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 22.19M | 35.28M | 44.43M | 33.99M |
| Accounts Payable | 7.33M | 6.37M | 2.50M | 4.04M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 7.33M | 6.37M | 2.50M | 4.04M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 7.33M | 6.37M | 2.50M | 4.04M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 14.86M | 28.91M | 41.93M | 29.96M |
| Common Par | 199.18M | 0.00 | 0.00 | 0.00 |
| Additional Paid In Capital | 24.25M | 194.34M | 174.60M | 139.09M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -208.89M | -167.91M | -138.74M | -113.44M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 321.44K | 2.48M | 6.07M | 4.31M |
| Total Capitalization | 14.86M | 28.91M | 41.93M | 29.96M |
| Total Equity | 14.86M | 28.91M | 41.93M | 29.96M |
| Total Liabilities & Stock Equity | 22.19M | 35.28M | 44.43M | 33.99M |
| Total Common Shares Outstanding | 76.71M | 71.25M | 67.96M | 61.55M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 76.10M | 70.91M | 62.48M | 49.37M |
| Diluted Weighted Shares Outstanding | 76.10M | 70.91M | 62.48M | 49.37M |
| Number of Employees | 23 | 25 | 17 | 14 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with ONCY
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- UserASCO 2010
- Userrussbow98 Portfolio 1
- Userwallacee Portfolio 1
- UserASCO 2009 Nymph's Watch List.
- Userdoom-n-gloom
- Userutopian_holdings
- Userjohndboyle Portfolio 1
- UserDenverbill1027 Portfolio 1
Latest ONCY Headlines from TheStreet
- Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech 04.05.13 | 07:04 am
- Biotech Stock Mailbag: Ziopharm, Oncolytics, Sarepta 03.01.13 | 06:03 am
- Why Expect More Price Swings From These 4 Biotechs 02.28.13 | 11:02 am
- Stocks Finish Higher Ahead of Fed Decision 09.12.12 | 05:09 pm
- Biotech Stock Mailbag: Oncolytics, Sarepta, Delcath, Peregrine 08.24.12 | 06:08 am
- 8 Stocks Under $10 Moving Higher 02.02.12 | 02:02 pm
- BIO CEO Conference Live Blog 02.14.11 | 02:02 pm
- Amgen Makes Bet on Viral Skin Cancer Killer 01.26.11 | 10:01 am
- Biotech's Brighter Corners 12.08.10 | 12:12 pm
- Columbia Laboratories, Cardionet: Early Volume Plays 06.01.10 | 09:06 am
Press Releases for ONCY
- Oncolytics Biotech® Inc. Meets Primary Overall Statistical Endpoint In U.S. Phase 2 Study Of REOLYSIN® In Squamous Cell Lung Cancer - PR Newswire 03.28.13 | 06:03 am
- Oncolytics Biotech® Inc. Completes Patient Enrollment In U.S. Phase 2 Study Of REOLYSIN® In Non-Small Cell Lung Cancer - PR Newswire 03.05.13 | 06:03 am
- Media Advisory - Oncolytics Biotech® Inc. To Present At RBC Capital Markets 2013 Healthcare Conference - PR Newswire 02.25.13 | 05:02 pm
- Oncolytics Biotech® Inc. Announces Closing Of Common Share Offering - PR Newswire 02.25.13 | 11:02 am
- Oncolytics Biotech® Inc. Announces Addition To Senior Management Team - PR Newswire 02.20.13 | 05:02 pm
- Oncolytics Biotech® Inc. Announces Pricing Of Common Share Offering - PR Newswire 02.20.13 | 09:02 am
- Oncolytics Biotech® Inc. Announces Common Share Offering - PR Newswire 02.19.13 | 04:02 pm
- Oncolytics Biotech® Inc. Announces Additional Positive REOLSYIN® Clinical Trial Data From Phase 2 Study In Squamous Cell Carcinoma Of The Lung - PR Newswire 02.08.13 | 06:02 am
- Oncolytics Biotech® Inc. Announces Positive REOLSYIN® Clinical Trial Data Presented At ASCO Gastrointestinal Cancers Symposium - PR Newswire 01.28.13 | 06:01 am
- Oncolytics Biotech Inc. Announces Positive Top Line REOLYSIN® Data For First Endpoint In Randomized Phase III Study In Head And Neck Cancers - PR Newswire 12.13.12 | 06:12 am
Partner Headlines for ONCY
- Oncolytics Moves On A Hot Streak Of Clinical Data - Seeking Alpha 02.12.13 | 08:02 am
- 5 Stocks Under $5 On Winning Streaks - Seeking Alpha 01.05.13 | 05:01 am
- UPDATE: Stifel Nicolaus Initiates Oncolytics Ciotech at Buy with $6 PT on Reolysin Cancer Focus - Benzinga 08.30.12 | 01:08 pm
- Hyper-Novel Investments For Targeting Cancer - Seeking Alpha 05.30.12 | 09:05 am
- Baker's Dozen Trying To Beat The Odds In Pancreatic Cancer - Seeking Alpha 10.25.11 | 08:10 am
- Company News for May 18, 2011 - Corporate Summary - Zacks 05.18.11 | 10:05 am
- Oncolytics Pushes Its Pipeline Further - Seeking Alpha 12.02.10 | 09:12 am
- Predictions for Biotech Data Heading to ASCO - Seeking Alpha 06.02.10 | 03:06 am
- Oncolytics Ready for Final Clinical Step With Reolysin - Seeking Alpha 05.20.10 | 10:05 am
